Medical artificial intelligence (AI) solution development company VUNO has received the Class IIa CE markings for five of its AI-based medical solutions.

VUNO Med-BoneAge, VUNO Med-DeepBrain, VUNO Med-Chest X-Ray, VUNO Med-Fundus AI and VUNO Med-LungCT AI are the solutions that have obtained the CE marking.

Following the approval, the company plans to market the products in 27 member states of the EU, the acceding countries and the European Free Trade Association (EFTA) states.

They will also be launched in countries in the Middle East, Asia, South and Central America and Africa where European CE mark is recognised.

The company noted that its Fundus AI, Chest X-ray, BoneAge and VUNO Med Lung CT AI solutions received regulatory approval based on the data from the clinical trials, which demonstrated its efficacy and safety.

VUNO Med – Fundus AI is developed to automatically detect a range of lesions from the fundus image and classify them for diagnosis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lung CT AI solution detects and quantifies pulmonary nodules that are likely to progress to lung cancer. It also automatically categorises Lung-RADS to help manage different pulmonary nodules.

The company’s Chest X-Ray solution is designed to detect the most common thoracic findings and diseases through chest X-ray images, while BoneAge helps to evaluate bone age based on a child’s left-hand X-ray image.

The company’s DeepBrain solution segments brain regions, using brain magnetic resonance imaging (MRI) data and quantifies the volumes of each region to offer atrophy volumetrics against the normative database. It also delivers an analysis report.

VUNO CEO Hyun-Jun Kim said: “We have been taking proper measures to ensure that VUNO’s products obtain classification commensurate with their intended purposes as medical diagnostic supporting tools.

“In this sense, obtaining CE certification for all five products holds a great significance, and this will be able to accelerate our push for much anticipated global supply of VUNO Med series all around the world.”

In April, VUNO Med-Fundus AI received Class III medical device approval from the Korean Ministry of Food and Drug Safety.